´ëÀåÁ÷Àå¾ÏȯÀÚ¿¡¼ ±¸Á¦¿ä¹ýÀ¸·Î¼ÀÇ 5-Fluorouracil Àå±â°£ Áö¼ÓÁ¤ÁÖ È¿°ú
Protracted Venous Infusion of 5-Fluorouracil as a Salvage Chemotherapy in Colorectal Cancer
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Çö½Ä
±è¿ø¼®/Á¤¼÷ÀÎ/ÀÌÁ¾ÅÂ/±è±âÇö/À±¼º¼ö/°¿ø±â/ÀÌÈ«±â/¹Ú±ÙÄ¥
KMID : 0360319990310010120
Abstract
¼·Ð
±¹³»¿¡¼µµ ½Ä»ýÈ°ÀÇ ¼±¸È¿Í ÇÔ²² ´ëÀåÁ÷Àå¾ÏÀÇ ¹ß»ý ºóµµ°¡ Á¡Â÷ Áõ°¡ÇÏ°í ÀÖ´Ù. ´ëÀå
Á÷Àå¾ÏÀº ±ÙÄ¡Àû ÀýÁ¦¼ú¸¸ÀÌ ¿ÏÄ¡¸¦ À§ÇÑ À¯ÀÏÇÑ ¹æ¹ýÀÌÁö¸¸, Áø´Ü ´ç½Ã ÀÌ¹Ì ¿ø°ÝºÎÀ§¿¡
ÀüÀÌ µîÀ» Æ÷ÇÔÇÏ´Â ÁøÇ༺ ´ëÀåÁ÷Àå¾ÏÀÇ °æ¿ì³ª Àç¹ßÇÑ °æ¿ìÀÇ ´ëºÎºÐ¿¡ À־ Ç×¾ÏÈ
Çпä¹ý¿¡ ÀÇÁ¸ÇÒ ¼ö ¹Û¿¡ ¾ø´Â ½ÇÁ¤ÀÌ´Ù.
´ëÀåÁ÷Àå¾Ï¿¡¼ÀÇ Ç×¾ÏÈÇпä¹ýÀº ´ëºÎºÐÀÇ Ç×¾ÏÁ¦°¡ ¶Ñ·ÇÇÑ È¿°ú¸¦ º¸ÀÌÁö ¸øÇÏ°í ÀÖÀ¸
¸ç, 5-fluorouracil(ÀÌÇÏ 5-FU)¸¸ÀÌ 20% ÀüÈÄÀÇ ¹ÝÀÀ·üÀ» º¸¿© ÇöÀç±îÁö Ç¥ÁØ Ä¡·á ¾àÁ¦·Î
¿©°ÜÁö°í ÀÖ´Ù. ±× µ¿¾È 5-FUÀÇ Ç×¾ÏÈ¿°ú¸¦ ±Ø´ëȽÃÅ°·Á´Â ¸¹Àº ³ë·ÂµéÀÌ ÀÌ·ç¾îÁ³À¸¸ç,
±× °á°ú leucovorin, methotrexateµîÀÇ »ýÈÇÐÀû Á¶ÀýÁ¦¸¦ º´ÇÕÇÔÀ¸·Î½á ´õ ³ªÀº ¹ÝÀÀ·üÀÌ
º¸°íµÇ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â 5-FUÀÇ Åõ¿© ¹æ¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Àå±â°£ Áö¼ÓÁ¤ÁÖ ¹æ
¹ýÀÌ Àû±Ø µµÀԵDZ⠽ÃÀÛÇÏ¿´´Ù. ÀÌ¿¡ ÀúÀÚµéÀº 5-FU¸¦ ±Þ¼ÓÁ¤ÁÖ ¶Ç´Â ´Ü±â°£ Áö¼ÓÁ¤ÁÖ(5
ÀÏ°£ Áö¼ÓÁ¤ÁÖ)¿¡ ºÒÀÀ¼ºÀÎ ´ëÀåÁ÷Àå¾Ï ȯÀÚ¿¡°Ô 5-FU¸¦ Àå±â°£ Áö¼ÓÁ¤ÁÖ(28ÀÏ°£ Áö¼ÓÁ¤
ÁÖ)ÇÏ¿© ±× È¿°ú ¹× ¾ÈÁ¤¼ºÀ» Æò°¡ÇÏ°íÀÚ ÇÏ¿´´Ù.
Purpose: The administration of 5-fluorouracil (5-FU) by protracted intravenous
infusion is an alterative to the bolus administration of 5-FU in patients with advanced
colorectal cancers. This study was performed to evaluate the response rate and toxicities
of protracted infusion of 5-FU in patients with advanced or recurrent colorectal cancers
who had been treated with 5-FU by bolus or short-term continuous administration.
Materials and Methods: Between March 1995 and June 1997, twenty-eight patients
with advanced colorectal cancer previously exposed to 5-FU based chemotherapy were
enrolled in this trial. Patients received 5-FU (250 §·/m2/day days 1-28) or
5-FU plus leucovorin (5-FU; 200 §·/m2/day days 1-28, leucovorin; 20 §·
/m2 ¥³ days 1, 8, 15, 21) by ambulatory infusion pump. Treatment course
was repeated every 42 days until disease progression.
Result: Twenty-eight patients entered. All 28 patients were assessable for response
and toxicity. Five (19%) patients achieved a partial response, with the median response
duration of 15 weeks (range; 7-22 weeks), and median survival time of entire patients
was 54 weeks (range 7-l5l+ weeks). Gastrointestinal toxicity, specifically stomatitis was
a major toxicity (grade 2, 12% ; grade 3, 4%), but hand-foot syndrome was less
frequent (5%) compared with other trials with protracted infusion of 5-FU reported in
the literature. Hematologic toxicity was generally of low grade.
Conclusion: Prolonged intravenous infusion of 5-FU can produce a response rate of
19% with low toxicity among patients refractory to bolus or short-term infusion of
5-FU.
Å°¿öµå
5-fluorouracil; Colorectal cancer; Protracted infusion; Salvage chemotherapy;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸